Scarica l'app Stockscreener
1.28
1.48%
0.01
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Pds Biotechnology Corporation Borsa (PDSB) Ultime notizie
PDSB’s Market Seesaw: Yearly Gains & Recent Declines – What to Expect? - investchronicle.com
Transcript : PDS Biotechnology CorporationSpecial Call - MarketScreener
PDS Biotechnology (NASDAQ:PDSB) Stock Rating Lowered by Wall Street Zen - Defense World
HC Wainwright Issues Pessimistic Estimate for PDSB Earnings - Defense World
PDS Biotechnology Co. (NASDAQ:PDSB) Shares Sold by Millennium Management LLC - Defense World
Two Sigma Investments LP Raises Stock Holdings in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
PDS Biotechnology (NASDAQ:PDSB) Receives Buy Rating from HC Wainwright - Defense World
PDS Biotech expands equity incentive plan By Investing.com - Investing.com Canada
PDS Biotech expands equity incentive plan - Investing.com
PDS Biotechnology Approves Equity Plan Amendment at Meeting - TipRanks
# H.C. Wainwright maintains Buy rating on PDS BIOTECHNOLOGY stock - Investing.com
# H.C. Wainwright maintains Buy rating on PDS BIOTECHNOLOGY stock By Investing.com - Investing.com UK
PDSB Biotechnology's Virtual Event to Discuss Advances in HPV16-Positive HNSCC | PDSB Stock News - GuruFocus
PDS Biotech to Host Key Opinion Leader Event to Discuss Versamune® HPV for the Treatment of HPV16+ HNSCC - The Manila Times
PDS Biotechnology Corporation to Host Webinar on HPV16-Positive HNSCC and Merck KN-689 Study - Nasdaq
Jane Street Group LLC Invests $58,000 in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
Northern Trust Corp Trims Stock Holdings in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
PDS Biotech reports steady survival rates in HPV16-positive HNSCC trial By Investing.com - Investing.com South Africa
2 Biopharmaceutical Stocks Focused on Cancer That Wall Street Predicts Will More Than Double - inkl
Take the Zacks Approach to Beat the Markets: StoneCo, Axon, Intuit in Focus - TradingView
PDSB: PDS Biotechnology Releases Promising Results from Versamune HPV Studies | PDSB Stock News - GuruFocus
PDS Biotechnology Publishes Versamune® HPV Abstracts at ASCO - TipRanks
PDS Biotech reports steady survival rates in HPV16-positive HNSCC trial - Investing.com India
Clinical Trial Breakthrough: PDS Biotech Achieves 30-Month Survival in Advanced Head and Neck Cancer Patients - Stock Titan
PDS Biotechnology files to sell 9.82M shares of common stock for holders - MSN
PDS Biotechnology (PDSB) Announces Plan to Offer 9.82 Million Sh - GuruFocus
PDS Biotechnology (PDSB) Plans Sale of 9.82 Million Shares | PDS - GuruFocus
PDS Biotechnology (PDSB) Announces Plan to Offer 9.82 Million Shares - GuruFocus
PDS Biotechnology (PDSB) Plans Sale of 9.82 Million Shares | PDSB Stock News - GuruFocus
Wall Street Zen Upgrades PDS Biotechnology (NASDAQ:PDSB) to “Hold” - Defense World
PDS Biotechnology Corporation (PDSB)’s Versamune HPV Surpasses Survival Benchmarks in Recurrent Head and Neck Cancer Trial - Insider Monkey
Q2 EPS Estimates for PDS Biotechnology Raised by B. Riley - Defense World
PDS Biotech reports extended survival in HPV cancer study - Investing.com Australia
PDS Biotech reports extended survival in HPV cancer study By Investing.com - Investing.com India
PDS Biotechnology Reports Promising Overall Survival Data for Versamune® HPV Combined with Pembrolizumab in HPV16-Positive Head and Neck Cancer - Nasdaq
PDS Biotech Announces Positive Extended Follow-Up Data for VERSATILE-002 and Additional Trials Evaluating Versamune® HPV to be Presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting - TradingView
PDS Biotech at A.G.P. Showcase: Versamune’s Promising Potential By Investing.com - Investing.com South Africa
PDS Biotech at A.G.P. Showcase: Versamune’s Promising Potential - Investing.com
PDS Biotech to Participate at the A.G.P. Virtual Annual Healthcare Company Showcase - The Manila Times
PDS Biotechnology Corporation (NASDAQ:PDSB) Q1 2025 Earnings Call Transcript - MSN
PDS Biotech outlines continued VERSATILE 003 Phase 3 expansion while advancing HPV16-positive head and neck cancer strategy - MSN
Raymond James Financial Inc. Takes $26,000 Position in PDS Biotechnology Co. (NASDAQ:PDSB) - Defense World
PDS Biotechnology Corp (PDSB) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... - Yahoo Finance
PDS Biotechnology Reports Q1 2025 Progress and Financials - TipRanks
PDS Biotech advances Phase 3 trial, reports Q1 financials By Investing.com - Investing.com Nigeria
PDS Biotechnology: Q1 Earnings Snapshot - Midland Daily News
EMV Capital portfolio company PDS Biotech advances cancer trial - Proactive Investors
PDS Biotech advances Phase 3 trial, reports Q1 financials - Investing.com Australia
Earnings call transcript: PDS Biotech’s Q1 2025 results show reduced losses - Investing.com
Transcript : PDS Biotechnology Corporation, Q1 2025 Earnings Call, May 14, 2025 - marketscreener.com
0.34%
7.69%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):